AU2002217384B2 - Anti-allergic complex molecules - Google Patents

Anti-allergic complex molecules Download PDF

Info

Publication number
AU2002217384B2
AU2002217384B2 AU2002217384A AU2002217384A AU2002217384B2 AU 2002217384 B2 AU2002217384 B2 AU 2002217384B2 AU 2002217384 A AU2002217384 A AU 2002217384A AU 2002217384 A AU2002217384 A AU 2002217384A AU 2002217384 B2 AU2002217384 B2 AU 2002217384B2
Authority
AU
Australia
Prior art keywords
peptide
seq
allergic
segment
succinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002217384A
Other languages
English (en)
Other versions
AU2002217384A1 (en
Inventor
Ronit Eisenberg
Tamar Raz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2002217384A1 publication Critical patent/AU2002217384A1/en
Assigned to RAMOT AT TEL AVIV UNIVERSITY LTD. reassignment RAMOT AT TEL AVIV UNIVERSITY LTD. Request for Assignment Assignors: ALLERGENE LTD.
Application granted granted Critical
Publication of AU2002217384B2 publication Critical patent/AU2002217384B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002217384A 2000-12-21 2001-12-20 Anti-allergic complex molecules Ceased AU2002217384B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14047300A IL140473A0 (en) 2000-12-21 2000-12-21 Anti-allergic complex molecules
IL140473 2000-12-21
PCT/IL2001/001186 WO2002050097A2 (en) 2000-12-21 2001-12-20 Anti-allergic complex molecules

Publications (2)

Publication Number Publication Date
AU2002217384A1 AU2002217384A1 (en) 2002-09-05
AU2002217384B2 true AU2002217384B2 (en) 2007-10-11

Family

ID=11074953

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002217384A Ceased AU2002217384B2 (en) 2000-12-21 2001-12-20 Anti-allergic complex molecules
AU1738402A Pending AU1738402A (en) 2000-12-21 2001-12-20 Anti-allergic complex molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU1738402A Pending AU1738402A (en) 2000-12-21 2001-12-20 Anti-allergic complex molecules

Country Status (7)

Country Link
US (3) US7112568B2 (https=)
EP (2) EP1891975A1 (https=)
JP (1) JP2005506276A (https=)
AU (2) AU2002217384B2 (https=)
CA (1) CA2432879A1 (https=)
IL (1) IL140473A0 (https=)
WO (1) WO2002050097A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009544A1 (en) * 1999-06-17 2007-01-11 Ronit Eisenberg Anti-allergic complex molecules
IL140473A0 (en) * 2000-12-21 2002-02-10 Allergene Ltd Anti-allergic complex molecules
IL130526A0 (en) * 1999-06-17 2000-06-01 Allergene Ltd Novel anti-allergenic agents
JP4498101B2 (ja) * 2004-11-04 2010-07-07 大鵬薬品工業株式会社 頭痛の予防及び／または治療剤
DE602007011202D1 (de) 2006-01-27 2011-01-27 Univ Wuerzburg J Maximilians Peptid zur hemmung von calcineurin
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
US9301999B2 (en) 2009-09-28 2016-04-05 Duke University Peptide, adjuvants, vaccines, and methods of use
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US9492544B2 (en) * 2013-04-11 2016-11-15 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987192A (en) * 1974-01-07 1976-10-19 The Upjohn Company Compositions and process of treatment
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6103692A (en) * 1996-03-12 2000-08-15 The General Hospital Corporation Inhibiting protein interactions
IL140473A0 (en) * 2000-12-21 2002-02-10 Allergene Ltd Anti-allergic complex molecules
IL130526A0 (en) * 1999-06-17 2000-06-01 Allergene Ltd Novel anti-allergenic agents

Also Published As

Publication number Publication date
EP1891975A1 (en) 2008-02-27
EP1478378A2 (en) 2004-11-24
AU1738402A (en) 2002-07-01
IL140473A0 (en) 2002-02-10
US20040137006A1 (en) 2004-07-15
WO2002050097A3 (en) 2004-09-16
US20090227768A1 (en) 2009-09-10
EP1478378A4 (en) 2005-06-08
US20060100141A1 (en) 2006-05-11
US7112568B2 (en) 2006-09-26
JP2005506276A (ja) 2005-03-03
CA2432879A1 (en) 2002-06-27
WO2002050097A2 (en) 2002-06-27
US7528110B2 (en) 2009-05-05

Similar Documents

Publication Publication Date Title
US20090227768A1 (en) Anti-Allergic Complex Molecules
US20230293644A1 (en) Anti-inflammatory peptides and composition comprising the same
US9296787B2 (en) Antitumor peptide and use thereof
KR20150011681A (ko) 파골 세포 분화 억제용 펩타이드 및 이의 용도
US20110143995A1 (en) Novel anti-allergic agents
EP1677815B1 (en) Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization.
EP2004680B1 (en) N-terminal vdac variants and uses thereof
US20070009544A1 (en) Anti-allergic complex molecules
WO2001026678A9 (en) Short segments of dap-kinase
EP0837129B1 (en) Epimorphin antagonist and process for producing the same
JP4283531B2 (ja) マスト細胞の細胞死誘発剤
US7811561B1 (en) MCT-1, a human oncogene
US9856300B2 (en) Dpy-30 binding peptides and methods of use
JP2025503500A (ja) セストリン－ｍａｐｋ複合体阻害剤
US7807626B2 (en) Tumor suppressor protein and nucleotide encoding same
Class et al. Patent application title: DPY-30 Binding Peptides Inventors: Pinfen Yang (Milwaukee, WI, US) Priyanka Sivadas (Milwaukee, WI, US) Assignees: Marquette University
CN111094357A (zh) 一类新的Bcl10聚合抑制剂及其应用
JP2002249439A (ja) Ｉｌ−６誘導性細胞死の抑制剤およびｉｌ−６誘導性細胞死の抑制方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RAMOT AT TEL AVIV UNIVERSITY LTD.

Free format text: FORMER APPLICANT(S): ALLERGENE LTD.

FGA Letters patent sealed or granted (standard patent)
GD Licence registered

Name of requester: ALLERGICA LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired